Markets

Sector Update: Healthcare Stocks Flat; Incyte Psoriasis Drug Show Effective in Phase 2 Study

Healthcare stocks:

JNJ: -0.47%

PFE: flat

ABT: flat

MRK: flat

AMGN: flat

Healthcare shares are flat in pre-market, while Incyte ( INCY ) said its INCB39110 drug to treat psoriasis showed efficacy as compared to patients treated with placebo in a phase 2 proof-of-concept clinical trial involving 50 patients.

The drug was well tolerated with no evidence of myelosuppression. INCY is flat at $40.38 in pre-market.

Valeant Pharmaceuticals International (VRX,VRX.TO) said Health Canada has approved its New Drug Submission for Jublia, while its Bausch & Lomb unit got U.S. Food and Drug Administration marketing clearance for a new disposable contact lenses.

Jublia is a topical solution to treat onychomycosis, a common and destructive nail infection caused predominantly by dermatophyte fungi.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INCY

Other Topics

Commodities